Log in
OTCMKTS:HGEN

Humanigen News Headlines

$9.77
+0.47 (+5.05 %)
(As of 09/25/2020 12:00 AM ET)
Add
Compare
Today's Range
$9.55
Now: $9.77
$10.60
50-Day Range
$1.99
MA: $13.90
$24.90
52-Week Range
$1.50
Now: $9.77
$33.95
Volume445,326 shs
Average Volume103,966 shs
Market Capitalization$490.34 million
P/E RatioN/A
Dividend YieldN/A
Beta-2.28

Headlines

Humanigen (OTCMKTS HGEN) News Headlines Today

Source:
DateHeadline
Humanigen (OTCMKTS:HGEN) Trading 5.1% Higher Humanigen (OTCMKTS:HGEN) Trading 5.1% Higher
americanbankingnews.com - September 25 at 8:18 PM
BioMedNewsBreaks – Humanigen Inc. (NASDAQ: HGEN) Secures $78.2M in Underwritten Public Offering - StreetInsider.comBioMedNewsBreaks – Humanigen Inc. (NASDAQ: HGEN) Secures $78.2M in Underwritten Public Offering - StreetInsider.com
streetinsider.com - September 25 at 1:40 PM
Humanigen (OTCMKTS:HGEN) Stock Price Down 9.8%Humanigen (OTCMKTS:HGEN) Stock Price Down 9.8%
americanbankingnews.com - September 24 at 7:37 PM
Humanigen inks manufacturing deal with Thermo Fisher for lenzilumabHumanigen inks manufacturing deal with Thermo Fisher for lenzilumab
seekingalpha.com - September 23 at 1:56 PM
Humanigen Collaborates With Thermo Fisher To Expand Manufacturing Capacity For Lenzilumab - NasdaqHumanigen Collaborates With Thermo Fisher To Expand Manufacturing Capacity For Lenzilumab - Nasdaq
nasdaq.com - September 23 at 8:55 AM
Humanigen Announces Thermo Fisher Partnership to Expand Manufacturing for COVID-19 Therapeutic Candidate Lenzilumab - Business WireHumanigen Announces Thermo Fisher Partnership to Expand Manufacturing for COVID-19 Therapeutic Candidate Lenzilumab - Business Wire
businesswire.com - September 23 at 8:55 AM
Humanigen to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit - Business WireHumanigen to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit - Business Wire
businesswire.com - September 22 at 10:54 PM
Form 424B3 HUMANIGEN, INC - StreetInsider.comForm 424B3 HUMANIGEN, INC - StreetInsider.com
streetinsider.com - September 22 at 5:49 PM
Humanigen Announces Closing of Public Offering of Common StockHumanigen Announces Closing of Public Offering of Common Stock
finance.yahoo.com - September 22 at 5:49 PM
Humanigen to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech SummitHumanigen to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
finance.yahoo.com - September 22 at 5:49 PM
Will Humanigen (NASDAQ:HGEN) Spend Its Cash Wisely? - Yahoo FinanceWill Humanigen (NASDAQ:HGEN) Spend Its Cash Wisely? - Yahoo Finance
finance.yahoo.com - September 22 at 12:53 AM
Will Humanigen (NASDAQ:HGEN) Spend Its Cash Wisely?Will Humanigen (NASDAQ:HGEN) Spend Its Cash Wisely?
finance.yahoo.com - September 21 at 2:52 PM
Form 8-K HUMANIGEN, INC For: Sep 17 - StreetInsider.comForm 8-K HUMANIGEN, INC For: Sep 17 - StreetInsider.com
streetinsider.com - September 21 at 9:50 AM
Humanigen, Inc.: Humanigen Announces Pricing of Public Offering of Common Stock and Commencement of Trading on Nasdaq Under the Symbol "HGEN"Humanigen, Inc.: Humanigen Announces Pricing of Public Offering of Common Stock and Commencement of Trading on Nasdaq Under the Symbol "HGEN"
finanznachrichten.de - September 18 at 9:57 AM
Humanigen prices stock offering at $8.50Humanigen prices stock offering at $8.50
seekingalpha.com - September 18 at 9:57 AM
Humanigen Announces Pricing of Public Offering of Common Stock and Commencement of Trading on Nasdaq Under the Symbol "HGEN"Humanigen Announces Pricing of Public Offering of Common Stock and Commencement of Trading on Nasdaq Under the Symbol "HGEN"
finance.yahoo.com - September 18 at 9:57 AM
Humanigen prices 8M-share IPO at $8.50 - Seeking AlphaHumanigen prices 8M-share IPO at $8.50 - Seeking Alpha
seekingalpha.com - September 18 at 4:57 AM
Humanigen Announces Pricing of Public Offering of Common Stock and Commencement of Trading on Nasdaq Under the Symbol “HGEN” - Business WireHumanigen Announces Pricing of Public Offering of Common Stock and Commencement of Trading on Nasdaq Under the Symbol “HGEN” - Business Wire
businesswire.com - September 17 at 11:50 PM
Humanigen, Inc.: Humanigen Announces Review of Lenzilumab Phase 3 Study in COVID-19 by Data Safety Monitoring BoardHumanigen, Inc.: Humanigen Announces Review of Lenzilumab Phase 3 Study in COVID-19 by Data Safety Monitoring Board
finanznachrichten.de - September 15 at 4:34 PM
Humanigen, Inc.: Humanigen Announces Proposed Public Offering of Common Stock and Subsequent Listing on NASDAQHumanigen, Inc.: Humanigen Announces Proposed Public Offering of Common Stock and Subsequent Listing on NASDAQ
finanznachrichten.de - September 15 at 4:34 PM
Humanigen teams up with Lonza for COVID-19 candidate lenzilumabHumanigen teams up with Lonza for COVID-19 candidate lenzilumab
seekingalpha.com - September 15 at 4:34 PM
Humanigen readies equity offeringHumanigen readies equity offering
seekingalpha.com - September 15 at 4:34 PM
Humanigen Inc. (HGEN) Announces Proposed 8M Share Common Offering; Reports Uplisting to NASDAQ - StreetInsider.comHumanigen Inc. (HGEN) Announces Proposed 8M Share Common Offering; Reports Uplisting to NASDAQ - StreetInsider.com
streetinsider.com - September 15 at 11:34 AM
Humanigen Announces Proposed Public Offering of Common Stock and Subsequent Listing on Nasdaq - Business WireHumanigen Announces Proposed Public Offering of Common Stock and Subsequent Listing on Nasdaq - Business Wire
businesswire.com - September 15 at 11:34 AM
Humanigen and Lonza Announce Collaboration to Expand Manufacturing of Humanigens COVID-19 Therapeutic Candidate Lenzilumab - Business WireHumanigen and Lonza Announce Collaboration to Expand Manufacturing of Humanigen's COVID-19 Therapeutic Candidate Lenzilumab - Business Wire
businesswire.com - September 15 at 6:33 AM
Humanigen and Lonza Announce Collaboration to Expand Manufacturing of Humanigen's COVID-19 Therapeutic Candidate LenzilumabHumanigen and Lonza Announce Collaboration to Expand Manufacturing of Humanigen's COVID-19 Therapeutic Candidate Lenzilumab
finance.yahoo.com - September 15 at 6:33 AM
Humanigen (OTCMKTS:HGEN) Reaches New 52-Week High at $10.94Humanigen (OTCMKTS:HGEN) Reaches New 52-Week High at $10.94
americanbankingnews.com - September 14 at 10:52 PM
2 No-Brainer Stocks to Buy in Biotech - Nasdaq2 No-Brainer Stocks to Buy in Biotech - Nasdaq
nasdaq.com - September 14 at 9:32 AM
Humanigen Announces Review of Lenzilumab Phase 3 Study in COVID-19 by Data Safety Monitoring Board - Business WireHumanigen Announces Review of Lenzilumab Phase 3 Study in COVID-19 by Data Safety Monitoring Board - Business Wire
businesswire.com - September 14 at 9:32 AM
Humanigen Announces Review of Lenzilumab Phase 3 Study in COVID-19 by Data Safety Monitoring BoardHumanigen Announces Review of Lenzilumab Phase 3 Study in COVID-19 by Data Safety Monitoring Board
finance.yahoo.com - September 14 at 9:32 AM
Humanigen (OTCMKTS:HGEN) Shares Scheduled to Reverse Split on Monday, September 14thHumanigen (OTCMKTS:HGEN) Shares Scheduled to Reverse Split on Monday, September 14th
americanbankingnews.com - September 10 at 1:40 AM
Humanigen, Inc.: Humanigen Announces One-for-Five Reverse Stock Split; Reverse Split Facilitates Potential Uplisting to NasdaqHumanigen, Inc.: Humanigen Announces One-for-Five Reverse Stock Split; Reverse Split Facilitates Potential Uplisting to Nasdaq
finanznachrichten.de - September 5 at 9:22 AM
Humanigen to effect 1-for-5 reverse stock split - Seeking AlphaHumanigen to effect 1-for-5 reverse stock split - Seeking Alpha
seekingalpha.com - September 5 at 12:59 AM
Humanigen Announces One-for-Five Reverse Stock Split - Business WireHumanigen Announces One-for-Five Reverse Stock Split - Business Wire
businesswire.com - September 4 at 7:59 PM
Humanigen Announces One-for-Five Reverse Stock Split; Reverse Split Facilitates Potential Uplisting to NasdaqHumanigen Announces One-for-Five Reverse Stock Split; Reverse Split Facilitates Potential Uplisting to Nasdaq
finance.yahoo.com - September 4 at 7:59 PM
Humanigen to Present at Upcoming Investor Conferences - Yahoo FinanceHumanigen to Present at Upcoming Investor Conferences - Yahoo Finance
finance.yahoo.com - September 2 at 11:50 PM
Humanigen, Inc.: Humanigen to Host Investor KOL Conference CallHumanigen, Inc.: Humanigen to Host Investor KOL Conference Call
finanznachrichten.de - September 2 at 8:36 AM
Humanigen to Present at Upcoming Investor ConferencesHumanigen to Present at Upcoming Investor Conferences
finance.yahoo.com - September 2 at 8:36 AM
Humanigen to Host Investor KOL Conference Call - Business WireHumanigen to Host Investor KOL Conference Call - Business Wire
businesswire.com - September 1 at 5:32 PM
Humanigen to Host Investor KOL Conference CallHumanigen to Host Investor KOL Conference Call
finance.yahoo.com - September 1 at 5:32 PM
Humanigens lenzilumab shows positive effect in COVID-19 in case-control studyHumanigen's lenzilumab shows positive effect in COVID-19 in case-control study
seekingalpha.com - September 1 at 12:31 PM
Lenzilumab COVID-19 Case-Control Study Published in Mayo Clinic Proceedings Journal - Business WireLenzilumab COVID-19 Case-Control Study Published in Mayo Clinic Proceedings Journal - Business Wire
businesswire.com - September 1 at 7:30 AM
Lenzilumab COVID-19 Case-Control Study Published in Mayo Clinic Proceedings JournalLenzilumab COVID-19 Case-Control Study Published in Mayo Clinic Proceedings Journal
finance.yahoo.com - September 1 at 7:30 AM
Humanigen Appoints Edward P. Jordan as Chief Commercial Officer - Business WireHumanigen Appoints Edward P. Jordan as Chief Commercial Officer - Business Wire
businesswire.com - August 24 at 9:32 AM
Seres Jumps On Data, And Other News: The Good, Bad And Ugly Of Biopharma - Seeking AlphaSeres Jumps On Data, And Other News: The Good, Bad And Ugly Of Biopharma - Seeking Alpha
seekingalpha.com - August 11 at 4:00 PM
Humanigen, Inc.: Humanigen Expands Phase III Study of Lenzilumab in COVID-19 to BrazilHumanigen, Inc.: Humanigen Expands Phase III Study of Lenzilumab in COVID-19 to Brazil
finanznachrichten.de - August 10 at 8:51 PM
Humanigen on go with COVID-19 study in BrazilHumanigen on go with COVID-19 study in Brazil
seekingalpha.com - August 10 at 8:51 PM
Humanigen Expands Phase III Study of Lenzilumab in COVID-19 to Brazil - Business WireHumanigen Expands Phase III Study of Lenzilumab in COVID-19 to Brazil - Business Wire
businesswire.com - August 10 at 3:50 PM
Marriott Posts Adj. Loss In Q2; Revenue Down 72% - NasdaqMarriott Posts Adj. Loss In Q2; Revenue Down 72% - Nasdaq
nasdaq.com - August 10 at 10:39 AM
Humanigen Expands Phase 3 Study Of Lenzilumab In COVID-19 To Brazil - Quick Facts - NasdaqHumanigen Expands Phase 3 Study Of Lenzilumab In COVID-19 To Brazil - Quick Facts - Nasdaq
nasdaq.com - August 10 at 10:39 AM
This page was last updated on 9/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.